GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sch 1 Update- Original Invest

27 Oct 2006 15:56

AIM27 October 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Original Investments plc to be renamed ViaLogy PlcCOMPANY ADDRESS:Ashcombe Court Woolsack Way Godalming Surrey COMPANY POSTCODE:GU7 1LQCOUNTRY OF INCORPORATION:EnglandCOMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:Original Investments plc is acquiring ViaLogy Corp ("ViaLogy"). This transaction constitutes a reverse takeoverfor the purposes of the AIM Rules. ViaLogy was founded in 1999 by a group of senior scientists and managers in supercomputing and ultra-computingtechnologies at the Caltech/NASA Jet Propulsion Laboratory (JPL) in Pasadena, California. Leveraging theirprior expertise and work at JPL in remote sensing and signal processing, ViaLogy scientists developed atechnology to separate the background 'noise' that envelops weak signals called Quantum ResonanceInterferometry (QRI). The initial test results on QRI, undertaken in the microarray industry, indicated that the technology was able to detect and discriminate signals with an intensity 1,000 times lower than RMS (root mean square)background noise. The technology was the subject of further development work undertaken in the massspectrometry industry. Other development activities were carried out in the areas of sensor data processing andtransference. The board and management team of ViaLogy consider that the technology is sufficiently advanced to be ofconsiderable benefit in a number of industrial areas and a planned programme of commercialisation hascommenced. Discussions at both development and commercial levels are being held with a number of internationalcompanies and national authorities to verify the suitability of incorporating the ViaLogy technology intoexisting and/or new products. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price towhich it seeks admission and the number and type to be held as treasury shares):403,256,437 ordinary shares with a nominal value of 0.01p per share and an issue price of 4p per share.CAPITAL TO BE RAISED ON ADMISSION:N/AFULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Directors James Derrick Slater, Chairman (to resign on Admission) Terence Bond, Managing Director and Deputy Chairman (to become Executive Chairman on Admission) Dr Richard Peter Dixey, Non Executive Director (Richard is due to retire at the AGM) Julian George Viggars, Non Executive Director (to resign on Admission) Proposed Directors Michael Woods Kelly, Proposed Chief Executive Dr Sandeep Gulati, Proposed Technical Director George Rehm, Proposed Non-Executive Director Dr Robert William Dean, Proposed Non-Executive Director PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARECAPITAL BEFORE AND AFTER ADMISSION: Shareholding Before Admission % Shareholding After Admission % James Derrick Slater 26,485,000 8.5 26,485,000 6.6Terence Bond 13,925,000 4.5 13,925,000 3.5 NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIMRULES:N/AANTICIPATED ACCOUNTING REFERENCE DATE:31 MarchEXPECTED ADMISSION DATE:31 October 2006NAME AND ADDRESS OF NOMINATED ADVISER:Seymour Pierce Limited Bucklersbury House 3 Queen Victoria Street London EC4N8ELNAME AND ADDRESS OF BROKER:Seymour Pierce Limited Bucklersbury House 3 Queen Victoria Street London EC4N8ELDETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:Seymour Pierce Limited Bucklersbury House 3 Queen Victoria Street London EC4N8ELDATE OF NOTIFICATION: 27 October 2006NEW/ UPDATE (see note):Update This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th May 20187:00 amRNSYear-end Trading Update and £2.5m Fundraising
30th Apr 20184:00 pmRNSNotice of Trading Update
29th Mar 20187:00 amRNSPremaitha to attend industry conferences in APAC
26th Mar 20187:00 amRNSUpdate on UK patent infringement claim
16th Feb 20187:00 amRNSPremaitha secures market entry into Egypt
14th Feb 201810:25 amRNSHolding(s) in Company
12th Feb 20187:00 amRNSThermo Fisher - issue of warrants
6th Feb 20187:00 amRNSPremaitha to attend key conferences in Middle East
5th Feb 20187:00 amRNSPremaitha's IONA test approved for sale in Brazil
24th Jan 20187:00 amRNSUK High Court grants right to appeal
22nd Jan 20187:00 amRNSSecured loan facility agreement with Thermo Fisher
29th Dec 20177:00 amRNSHalf Year Results
11th Dec 20177:00 amRNSPremaitha secures four further laboratories in EU
1st Dec 20179:40 amRNSPremaitha CEO Wins Outstanding Contribution Award
27th Nov 20177:00 amRNSMiddle East laboratory network expansion
23rd Nov 20177:00 amRNSPremaitha signs new partner in East Asia
21st Nov 201710:47 amRNSLitigation First Instance Judgment
30th Oct 201710:08 amRNSGrant of Share Options
24th Oct 20173:45 pmRNSResult of AGM
24th Oct 20177:00 amRNSAGM Statement
13th Oct 20177:00 amRNSMiddle East Update
29th Sep 20177:04 amRNSFinal Results
29th Sep 20177:01 amRNSNotice of AGM
21st Sep 20174:05 pmRNSHolding(s) in Company
19th Sep 20177:00 amRNSPremaitha to offer NIPT in South Africa
7th Sep 20173:10 pmRNSFurther Patent Infringement Claims
29th Aug 20177:00 amRNSApproved for Good Manufacturing Process in Brazil
18th Jul 20172:02 pmRNSHolding(s) in Company
12th Jul 20177:00 amRNSInvestment Agreement Extension with Thermo Fisher
10th Jul 20177:00 amRNSPremaitha announces two laboratory hub contracts
3rd Jul 20177:00 amRNSLitigation Update
27th Jun 20177:00 amRNSHolding(s) in Company
16th Jun 20177:00 amRNSPremaitha launches Sage NIPT solution
5th Jun 20177:00 amRNSIndia Business Update
26th May 20177:00 amRNSIONA test validation on Thermo Fisher's Ion S5
19th May 20172:30 pmRNSPremaitha welcomes NIPT recommendation in France
16th May 20177:00 amRNSYear End Trading Update
12th May 20172:15 pmRNSUpdate Re. Swiss Customer
3rd Apr 20174:48 pmRNSHolding(s) in Company
31st Mar 20174:00 pmRNSSecond tranche of warrants issued to Thermo Fisher
17th Mar 20177:15 amRNSHardman Research: Expanding global distribution
13th Mar 20177:00 amRNSPremaitha to Attend International Medical Events
2nd Mar 201711:03 amRNSCompletion of Yourgene Acquisition
27th Feb 20177:00 amRNSCompletion of Acquisition
22nd Feb 20179:37 amRNSHolding(s) in Company
20th Feb 20177:00 amRNSMiddle East Business Update
16th Feb 20175:34 pmRNSHolding(s) in Company
15th Feb 20177:00 amRNSIssue of Equity
14th Feb 20179:32 amRNSHolding(s) in Company
13th Feb 20177:00 amRNSNew partnership with European diagnostics group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.